tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Galapagos Appoints Fred Blakeslee as General Counsel

Story Highlights
Galapagos Appoints Fred Blakeslee as General Counsel

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Galapagos ( (GLPG) ) is now available.

On October 16, 2025, Galapagos NV announced the appointment of Fred Blakeslee as Executive Vice President and General Counsel, succeeding Valeria Cnossen. Blakeslee, who brings extensive legal expertise and experience in high-impact partnerships, is expected to play a crucial role in Galapagos’ strategic transformation and growth. His previous role at AbbVie involved leading legal teams in significant mergers and acquisitions, including the $63 billion acquisition of Allergan PLC. This leadership transition is seen as a pivotal step in advancing Galapagos’ clinical pipeline and enhancing its position in the biopharmaceutical industry.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

Galapagos’ overall stock score is primarily impacted by its financial performance, which is currently weak due to significant profitability and cash flow challenges. The technical analysis provides some positive momentum, but the overbought conditions suggest caution. The valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a moderate overall score.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos is a biotechnology company operating in Europe, the U.S., and Asia, focused on transforming patient outcomes through innovative science and technology. The company aims to address high unmet medical needs by developing a deep pipeline of best-in-class medicines, utilizing a decentralized cell therapy manufacturing platform, and challenging the status quo to deliver results for patients, employees, and shareholders.

Average Trading Volume: 277,869

Technical Sentiment Signal: Buy

Current Market Cap: $2.25B

Find detailed analytics on GLPG stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1